https://www.taxtmi.com/news?id=51069 VedTechBio advertises enhanced RxAgentAI capabilities and a strategic collaboration with AlphaMeld to co-develop therapies from preclinical discovery through human proof-of-concept. The platform is an autonomous multi-agent intelligence system employing an expert-in-the-loop mode to integrate human oversight with agent outputs, claimed to shorten target identification and compress full discovery workflows. The alliance is framed to advance translational readiness and attract commercial partnerships with major pharmaceutical companies. en-us Thu, 31 Jul 2025 11:31:03 +0530 Thu, 31 Jul 2025 11:31:04 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=51069 VedTechBio advertises enhanced RxAgentAI capabilities and a strategic collaboration with AlphaMeld to co-develop therapies from preclinical discovery through human proof-of-concept. The platform is an autonomous multi-agent intelligence system employing an expert-in-the-loop mode to integrate human oversight with agent outputs, claimed to shorten target identification and compress full discovery workflows. The alliance is framed to advance translational readiness and attract commercial partnerships with major pharmaceutical companies. News - Thu, 31 Jul 2025 11:31:03 +0530 https://www.taxtmi.com/news?id=51069